Drug Profile
Research programme: neurological disorders cell therapy - Cryo-Cell/Saneron CCEL Therapeutics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Cryo-Cell International; Saneron CCEL Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Neurological-disorders in USA
- 29 Jan 2008 Preclinical trials in Neurological disorders in USA (unspecified route)